Posted on

One dose of psilocybin eases migraines in recent study

A single dose of psilocybin has a lasting therapeutic effect on migraine headache, according to a new placebo-controlled study

A double-blind, placebo-controlled study found that a single low dosage of psilocybin effectively reduced the severity of migraine pain and functional impairments in participants with frequent migraines. Participants reported that the therapeutic effect lasted for at least two weeks with no adverse side effects, supporting years of anecdotal reports that psilocybin eases migraine symptoms.

PDF of article

Posted on

Core One Labs has initiated the development of patent-pending drug formulation that uses psilocybin to treat the underlying cause of Alzheimer’s Disease

Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease

Akome Biotech Ltd., a subsidiary of Core One Labs Inc. (COOL), has initiated the development of patent-pending drug formulation made of psilocybin and a plant bioactive compound, which is believed to help treat Alzheimer’s Disease. While current Alzheimer’s treatments focus on treating symptoms of the disease, the new drug formulation known as AKO002 aims to treat the underlying cause of the disease by targeting serotonin receptors in the hippocampus. Data mapping reveals that psychedelics like psilocybin have “positive effects in the promotion of neuroplasticity and neurogenesis” and have “potent anti-inflammatory properties”.

PDF of article

Posted on

The psychedelic drugs market is expected to reach $10.75 billion USD by 2027, growing at a 12.36% CAGR

Psychedelic Drugs Market Size Is Projected To Reach $10.75 Billion By 2027

A recent report from Research And Markets predicts that the psychedelic drugs market will grow at a 12.36% compound annual growth rate from 2021 to 2027, reaching $10.75 billion USD by 2027. The rapid acceptance of the medical applications of psychedelics in the mental health sector fuels the growth of the market.

PDF of article

Posted on

Losing weight with shrooms?

Psychedelic drug users tend to have better overall physical health than non-users, study finds

Psychedelic drug users might be healthier than non-users, according to a recent study.

A survey of over 170,000 people showed that those who have used psychedelic drugs (14% of respondents) reported better overall health and were significantly less likely to be overweight or obese compared to non-users. The University of Oxford researchers suggest that transcendent psychedelic experiences might result in “long-term changes in health behavior that contribute to better physical health.”

PDF of article

PDF of study

Posted on

The ATMA Urban Journey Clinic became the first clinic in Alberta to use psilocybin-assisted therapy and will become a Canada-wide training center for mental health professionals

Psychedelic drug therapy now offered at Calgary clinic, the first of its kind in Alberta

The ATMA Urban Journey Clinic in Calgary began psilocybin treatment for a terminal cancer patient, making it the first clinic in Alberta to use psychedelic therapy. Clinic CEO David Harder explains that psilocybin treatment brings out suppressed emotions, allowing patients and therapists to work through them together, whereas typical medications numb down the emotions. The cancer patient claims that he “couldn’t be more at peace” during the treatment, giving hope that psilocybin-assisted therapy will continue to gain traction. The clinic will become a training center for mental health professionals across the country.

PDF of article

Posted on

Psychiatry professor believes that psilocybin has potential to reset the behaviours and cognitions of those with eating disorders by changing neural pathways.

Magic mushrooms’ for eating disorders? Drug company running trials at B.C. university

Dr. C. Laird Birmingham, Psychiatry professor with expertise in eating disorders, believes that psilocybin has potential to reset the behaviours and cognitions of those with eating disorders by changing neural pathways. NeonMind Biosciences Inc. is working with Dr. Birmingham at the University of British Columbia in preclinical trials to determine if psilocybin could be used to change the unconscious response to emotional situations that can trigger food-related addictions.

PDF of article

Posted on

Vancouver may decriminalize possession of drugs including psychedelics

Vancouver, Health Canada to formally discuss drug decriminalization, mayor says

In an effort to tackle the ongoing overdose crisis in Vancouver, Health Canada has agreed to discuss a plan to decriminalize the possession of small amounts of illicit drugs. The city council of Vancouver voted unanimously to put the idea forward to the federal government back in November 2020. Mayor Kennedy Stewart is hopeful that if granted the exemption, Vancouver will see a decline in drug-related deaths after a record number of overdoses in 2020.

PDF of article

Posted on

A world-renowned addictions specialist claims that psychedelics have “potential to be the equivalent of a cure for cancer in the mental health space”

Documentary explores use of psychedelic drugs for mental health issues

In a new documentary, VeraCity: The Psychedelic Frontier, a world-renowned addictions specialist claimed that psychedelics have “potential to be the equivalent of a cure for cancer in the mental health space”. The documentary explores Canada’s leading research on psilocybin and follows a Toronto war hero’s journey to heal his mind from PTSD using a psychedelic plant called Iboga.

PDF of article

Posted on

A BC man no longer experiences panic attacks or other PTSD symptoms after microdosing psilocybin for 8 months

One man’s experience with magic mushrooms

A BC man claims that microdosing psilocybin for 8 months has eased his PTSD symptoms tremendously. The man states that he no longer experiences panic attacks and believes that psilocybin represents “freedom from being stuck in a dark place in your head”. The documentary VeraCity: The Psychedelic Frontier dives deeper into his journey through PTSD.

Posted on

Psilocybin-assisted therapy 4 times more effective than antidepressants

Psilocybin-assisted psychotherapy produces large, rapid, and sustained antidepressant effects

A clinical trial showed psilocybin-assisted therapy was 4 times more effective at treating major depressive disorder than antidepressant drugs. 27 participants with a long-term history of depression received 11 hours of therapy in addition to two full-day psilocybin-assisted therapy sessions, two weeks apart. Patients received the doses of psilocybin while lying on a couch with eyeshades and listening to music through headphones, and clinical monitors provided guidance and support throughout the experience. Four weeks after the treatment, 71% of participants saw at least a 50% reduction in depression scores, and 54% of participants were in remission from depression.

PDF of article